Athebio
Athebio is a bootstrapped biotech company founded in 2019 and headquartered in Zurich, Switzerland. They specialize in drug discovery and biotherapeutic engineering, leveraging their proprietary Athebody® platform. This platform integrates DARPins (Designed Ankyrin Repeat Proteins) with an efficient discovery engine to create targeted biotherapeutics with high specificity, efficacy, and safety. Athebio's business model is centered on strategic partnerships and technology transfer, providing drug developers with access to their DARPin technology to create innovative biological solutions. They have demonstrated successful applications in developing targeted-AAV, LNP, pHLA-binding TCEs, and targeted radiotherapy.
Athebio
Athebio is a bootstrapped biotech company founded in 2019 and headquartered in Zurich, Switzerland. They specialize in drug discovery and biotherapeutic engineering, leveraging their proprietary Athebody® platform. This platform integrates DARPins (Designed Ankyrin Repeat Proteins) with an efficient discovery engine to create targeted biotherapeutics with high specificity, efficacy, and safety. Athebio's business model is centered on strategic partnerships and technology transfer, providing drug developers with access to their DARPin technology to create innovative biological solutions. They have demonstrated successful applications in developing targeted-AAV, LNP, pHLA-binding TCEs, and targeted radiotherapy.